Duchenne News Tags: Edgewise

June 27, 2023
Edgewise Therapeutics announces positive 12-month topline results from the ongoing ARCH study for Becker muscular dystrophy
April 7, 2023
On March 30, 2023, Edgewise Therapeutics announced the publication of the article, “Modulating fastskeletal muscle contraction protects skeletal muscle in the animal models of Duchenne muscular dystrophy,” in the Journal...
September 12, 2022
On Sept. 12, 2022, Edgewise Therapeutics released positive 4-month interim data from their open label study in individuals with Becker muscular dystrophy.
September 7, 2022
On Sept. 7, 2022, Edgewise announced that the FDA has authorized its Phase 2 clinical trial for the treatment of Duchenne. They expect to begin dosing participants in the fourth...
July 14, 2022
On July 12, 2022, Edgewise Therapeutics shared a press release announcing the opening of the CANYON Phase 2 clinical trial of their investigational compound, EDG-5506, in individuals with Becker muscular...
Edgewise Duchenne News
June 21, 2022
On June 20, 2022, Edgewise Therapeutics announced positive results from the ARCH open label study of EDG-5506.

Experience the magic of camp promise

Complete applications due April 3, 2023.